Brawn Biotech Limited (BOM:530207)
18.60
-0.45 (-2.36%)
At close: Feb 11, 2026
Brawn Biotech Revenue
Brawn Biotech had revenue of 48.91M INR in the quarter ending September 30, 2025, with 48.36% growth. This brings the company's revenue in the last twelve months to 168.03M, up 23.10% year-over-year. In the fiscal year ending March 31, 2025, Brawn Biotech had annual revenue of 134.75M, down -18.30%.
Revenue (ttm)
168.03M
Revenue Growth
+23.10%
P/S Ratio
0.33
Revenue / Employee
18.67M
Employees
9
Market Cap
55.81M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 134.75M | -30.19M | -18.30% |
| Mar 31, 2024 | 164.95M | -57.42M | -25.82% |
| Mar 31, 2023 | 222.36M | 136.15M | 157.93% |
| Mar 31, 2022 | 86.21M | -263.55M | -75.35% |
| Mar 31, 2021 | 349.76M | -146.41M | -29.51% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vivanza Biosciences | 663.49M |
| Cian Healthcare | 232.80M |
| Fabino Enterprises | 204.36M |
| Beryl Drugs | 176.65M |
| Decipher Labs | 176.11M |
| Unjha Formulations | 148.12M |
| Ganga Pharmaceuticals | 26.93M |
| Rekvina Laboratories | 5.42M |